5973-28-4

Basic information

• Product Name: 7-chloro-1-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione
• CAS NO: 5973-28-4
• Molecular Formula: C₁₀H₉ClN₂O₂
• Molecular Weight: 224.6437
• Mol File: 5973-28-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 611.4°C at 760 mmHg
• Flash Point: 323.5°C
• Density: 1.352g/cm³
• Vapor Pressure: 6.93E-15mmHg at 25°C
• Refractive Index: 1.579
• CAS DataBase Reference: 7-chloro-1-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 7-chloro-1-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione(5973-28-4)
• EPA Substance Registry System: 7-chloro-1-methyl-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione(5973-28-4)

Safety Data

• Hazardous Substances Data: 5973-28-4(Hazardous Substances Data)

Upstream product

• 14529-12-5 6-chloro-N-methylisatoic anhydride 
• 56-40-6 glycine 
• 1022-13-5 5-chloro-2-(methylamino)benzophenone 
• 4743-17-3 5-Chloroisatoic anhydride 
• 10379-14-3 tetrazepam 
• 72952-52-4 potassium 5-chloro-2-(methylamino)hippurate 
• 72952-48-8 N-acetyl-7-chloro-3,4-dihydro-1-methyl-1H-1,4-benzodiazepine-2,5-dione 
• 72952-53-5 5-chloro-2-(methylamino)hippuric acid 
• 54888-03-8 5-chloro-2-(aceturoylmethylamino)benzophenone 

Downstream Products

• 72952-51-3 N-{[(2-Benzoyl-4-chloro-phenyl)-methyl-carbamoyl]-methyl}-isobutyramide 
• 1059064-05-9 7-chloro-5-(4-hydroxyphenyl)-1-methyl-3-(4-(trifluoromethyl)benzyl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059066-03-3 7-chloro-5-(4-(4-methoxybenzyloxy)phenyl)-1-methyl-3-(4-(trifluoromethyl)benzyl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059066-02-2 7-chloro-5-(4-(4-methoxybenzyloxy)phenyl)-1-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059063-99-8 7-chloro-3-(2-chlorobenzyl)-5-(4-hydroxyphenyl)-1-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059065-60-9 7-chloro-3-(2-chlorobenzyl)-5-(4-methoxyphenyl)-1-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059065-59-6 7-chloro-5-(4-methoxyphenyl)-1-methyl-3-(2-methylbenzyl)-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059065-47-2 (E)-3-(2-bromobenzyl)-5,7-dichloro-1-methyl-1H-benzo[e][1,4]diazepin-2(3H)-one 
• 1059064-02-6 3-(2-bromobenzyl)-7-chloro-1-methyl-5-(2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)-1H-benzo[e][1,4]diazepin-2(3H)-one 

Relevant articles and documents

BENZODIAZEPINONE COMPOUNDS AND METHODS OF TREATMENT USING SAME

The invention provides 1,4-benzodiazepinone compounds, pharmaceutical compositions, and methods of treating autoimmune disorders, chronic inflammatory disorders, and hyperproliferative disorders. For example, the 1,4-benzodiazepinone compounds and pharmaceutical compositions are contemplated to be useful for treating rheumatoid arthritis, graft-versus-host disease, inflammatory bowel disease, and the like.

COMPOSITIONS AND METHODS RELATING TO NOVEL COMPOUNDS AND TARGETS THEREOF

The present invention relates to novel chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides benzodiazepine compounds, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with the faulty regulation of the processes of programmed cell death, autoimmunity, inflammation, hyperproliferation, vascular abnormalities, and the like.

Autoxidation of tetrazepam in tablets: Prediction of degradation impurities from the oxidative behavior in solution

The major route of degradation of tetrazepam (1) is oxidation to 7-chloro- 5-(3-keto-cyclohexen-1-yl)-1,3-dihydro-1-methyl-2H-1,4-benzodiazepin-2-one (3) via the stable 7-chloro-5-(3-hydroperoxy-cyclohexen-1-yl)-1,3-dihydro-1- methyl-2H-1,4 benzodiazepin-2-one (2). Minor degradation products are 7- chloro-5-(1,2-epoxycyclohexan-1-yl)-1,3-dihydro-1-methyl-2H-1,4- benzodiazepin-2-one (5) and 7-chloro-1,3-dihydro-1-methyl-2H-1,4- benzodiazepin-2,5-dione (4), resulting from cleavage of the C-C bond between the cyclohexene ring and the benzodiazepine ring. After 48 h, AIBN (2,2'- azobis[2-methyl-propanenitrile]) in acetonitrile at 40 °C produced qualitatively the same impurities as those observed in the stability study of tablets of 1. Other stress tests (thermal stress at 80 °C, heavy metal oxidation, hydrogen peroxide, acid-catalyzed oxidation) caused qualitatively different profiles of degradation.